- Home
- EWTX vs DMLP Comparison
EWTX vs DMLP Comparison
Compare EWTX & DMLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EWTX
- DMLP
- Stock Information
- Founded
- EWTX 2017
- DMLP 2003
- Country
- EWTX United States
- DMLP United States
- Employees
- EWTX N/A
- DMLP N/A
- Industry
- EWTX Biotechnology: Pharmaceutical Preparations
- DMLP Oil & Gas Production
- Sector
- EWTX Health Care
- DMLP Energy
- Exchange
- EWTX Nasdaq
- DMLP Nasdaq
- Market Cap
- EWTX 1.2B
- DMLP 1.4B
- IPO Year
- EWTX 2021
- DMLP N/A
- Fundamental
- Price
- EWTX $14.70
- DMLP $27.75
- Analyst Decision
- EWTX Buy
- DMLP
- Analyst Count
- EWTX 8
- DMLP 0
- Target Price
- EWTX $40.13
- DMLP N/A
- AVG Volume (30 Days)
- EWTX 1.2M
- DMLP 84.6K
- Earning Date
- EWTX 05-08-2025
- DMLP 05-08-2025
- Dividend Yield
- EWTX N/A
- DMLP 11.40%
- EPS Growth
- EWTX N/A
- DMLP N/A
- EPS
- EWTX N/A
- DMLP 2.13
- Revenue
- EWTX N/A
- DMLP $154,639,000.00
- Revenue This Year
- EWTX N/A
- DMLP N/A
- Revenue Next Year
- EWTX N/A
- DMLP N/A
- P/E Ratio
- EWTX N/A
- DMLP $12.74
- Revenue Growth
- EWTX N/A
- DMLP N/A
- 52 Week Low
- EWTX $10.60
- DMLP $25.84
- 52 Week High
- EWTX $38.12
- DMLP $34.88
- Technical
- Relative Strength Index (RSI)
- EWTX 42.22
- DMLP 42.13
- Support Level
- EWTX $14.08
- DMLP $26.97
- Resistance Level
- EWTX $17.30
- DMLP $29.95
- Average True Range (ATR)
- EWTX 1.00
- DMLP 0.72
- MACD
- EWTX 0.39
- DMLP -0.11
- Stochastic Oscillator
- EWTX 37.50
- DMLP 26.17
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.